Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
暂无分享，去创建一个
M. Konopleva | H. Kantarjian | A. Lane | G. Martinelli | N. Daver | D. DeAngelo | E. Deconinck | N. Pemmaraju | D. Rizzieri | E. Wang | H. Erba | K. Sweet | P. Zweidler-McKay | P. Montesinos | E. Todisco | C. Tarella | C. Sloss | Nikolaos Papadantonakis | K. Culm-Merdek